AstraZeneca Reports H1 2019 Revenue with Osimertinib Sales Reaching $1.414 Billion

On July 25, AstraZeneca announced its financial results for the first half of 2019, with total revenue reaching $11.314 billion, a year-on-year increase of 9%. Among this, revenue from the China region was $2.408 billion, up 27% year on year, while revenue from the oncology business in China amounted to $635 million, representing a 58% growth.

AstraZeneca’s Core Drug Sales Revenue in H1 2019 (USD billion)

Original Title: H1 2019, AstraZeneca's Core Drug Sales Revenue! Osimertinib $1.414 Billion